employer glp-1 coverage news Perspectives from Employers on the Costs and Issues Associated with Covering Agonists for Weight Loss Some US employers to drop

10.1161/CIRCRESAHA.107.162800 47 DruckerD

While Alnylams Phase III APOLLO-B study hit both key primary and secondary endpoints, the FDA stated in the documents that the effects of patisiran compared to placebo on both endpoints were small, of questionable clinical meaningfulness, and may not be detectable by patients. Major discussion points during the adcomm meeting included whether these key endpoints were appropriate to ascertain clinical meaningfulness in the ATTR-CM population, and panelists expressed varying opinions on whether the magnitude of the benefit seen in trial data was clinically meaningful

View study It is worth being careful with what that finding means

We'll break down availability, quality, and cost for each, and explain why most researchers end up buying online

Its clinical consideration column says a dose reduction is often required and close glucose monitoring is essential

Water is the most abundant greenhouse gas (a gas that absorbs and re-radiates heat) in Earths atmosphere